Wacker Chemie AG Financial Results FY 2025 | Restructuring, Cost Cuts & Recovery Outlook
Investor Snapshot
- COMPANY
- Wacker Chemie AG
- FORMAT
- Financial Results
- DURATION
- 22:39
- PUBLISHED
- March 2026
- LANGUAGE
- English
In 60 Seconds
Joerg Hoffmann presents Wacker Chemie AG FY 2025 results covering weak markets restructuring PACE cost cuts segment pressure and the 2026 recovery outlook
March 11, 2026
22:39 
Wacker Chemie AG FY 2025: Key Takeaways
Presented by Joerg Hoffmann, Head of Investor Relations
Wacker Chemie AG presented its full year 2025 financial results, with Joerg Hoffmann, Head of Investor Relations, guiding investors through a difficult but strategically important reporting period that may mark the turning point in the company’s current earnings cycle.
The FY 2025 presentation is significant because it combines two elements that investors care deeply about in cyclical industrial and chemical names: first, a clear acknowledgment of operational weakness, and second, a decisive strategic response. WACKER’s results show that 2025 was one of the most challenging years in recent memory, as weak demand, pricing pressure, elevated energy costs in Germany, and continued overcapacity in key chemical markets weighed on earnings across multiple divisions. Public reports around the annual release indicate that group sales declined 4% to €5.49 billion, reported EBITDA fell 43% to €427 million, and the company posted a net loss of €805 million.
FY 2025 as a Reset Year Rather Than Just a Weak Year
At first glance, those numbers are clearly weak. But the deeper capital-markets message is more nuanced. FY 2025 appears to be a reset year rather than simply a bad year. The company also reported EBITDA before special effects of €529 million, suggesting that while the underlying business was under pressure, the reported figures were further impacted by restructuring charges and other non-recurring items tied to strategic action.
PACE: The Largest Cost-Saving Initiative in WACKER’s History
That strategic action is the centerpiece of the presentation: the launch of PACE, the largest cost-saving initiative in WACKER’s history. The program targets more than €300 million in annual savings by 2027–2028 and includes major reductions in fixed production and administrative costs, as well as more than 1,500 job cuts.
This is a major signal to investors that management is not waiting for the cycle to improve on its own. Instead, WACKER is actively resizing its cost base to rebuild profitability and improve competitiveness.
Segment Performance: Broad-Based Pressure Across the Portfolio
From a segment perspective, the results show that pressure was broad-based. Silicones remained the largest division and held up comparatively better, with only a modest EBITDA decline despite weaker market conditions.
Polymers suffered from continued softness in construction-related demand, while Biosolutions remained strategically interesting but too small to offset broader weakness.
Polysilicon, one of the most closely watched businesses, experienced a sharp earnings decline as margin pressure intensified in a volatile market environment. This broad-based weakness is important because it explains why the group could not rely on diversification alone to protect earnings in 2025.
From Cyclical Exposure to Active Turnaround Story
For investors, the most important takeaway is that WACKER is now shifting from a passive cyclical story to a more active turnaround and self-help story. The company is not only waiting for better end-market demand in silicones, polymers, and polysilicon. It is also restructuring internally, reducing fixed costs, preserving liquidity, and resetting the earnings base.
The decision not to propose a dividend for FY 2025 should also be seen in this context. Rather than defending a payout during a weak year, management is prioritizing competitiveness and financial flexibility.
2026 Outlook: Gradual Recovery, Not a Full Rebound
The 2026 outlook reinforces this interpretation. Public sources indicate that WACKER expects low single-digit sales growth and EBITDA in a range of €550 million to €700 million.
That is clearly an improvement over 2025, but it is not framed as a full rebound. Instead, it suggests a gradual recovery supported by both cyclical normalization and internal cost savings from PACE. This kind of guidance is often more credible in difficult sectors than an overly optimistic recovery narrative.
Investment Perspective
Overall, Wacker Chemie’s FY 2025 financial results are important not because they show strength today, but because they may define the trough and the beginning of the next phase. The company remains strategically relevant in specialty chemicals, silicones, and advanced materials, and now has a quantified restructuring framework that could materially improve earnings power over time.
For investors focused on European chemicals and cyclical recovery stories, the FY 2025 presentation by Joerg Hoffmann is less about the past year’s weakness and more about whether WACKER has now created the basis for a more durable margin and cash flow recovery.
- WACKER FY 2025 Comments
- PACE Cost Project Launched in October 2025, First Measures Underway With Total Savings Of >€300 Million Per Year Targeted
- FY 2026 Outlook
- Investing To Expand Global Leadership Positions
- Strategic Priorities
- 2025 EBITDA at €529m Before Restructuring Expenses
- Strong Financials With A High Level Of Liquidity At €1.48bn And €3.76bn In Equity
- Silicones
- Polymers
- Biosolutions
- Polysilicon
- Others
- Net Debt Increased to €886 Million
- Appendix
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG
Unlock the insights of top publicly listed companies with seat11a.com